EBR Systems Lands HCA Healthcare Deal Unlocking 190 US Hospitals for WiSE
EBR Systems secures purchasing agreement with HCA Healthcare network
EBR Systems (ASX: EBR), developer of the world’s only leadless cardiac pacing device for heart failure, has secured a purchasing agreement with HCA Healthcare, one of the largest healthcare networks in the United States. HCA Healthcare operates 190 hospitals and approximately 2,500 ambulatory sites of care across 19 states, making this a meaningful commercial milestone in EBR’s U.S. rollout of its WiSE CRT System.
The agreement streamlines procurement and contracting pathways for the WiSE CRT System across HCA Healthcare hospitals, giving EBR sales reps direct access to engage with physicians and administrators at HCA sites.
John McCutcheon, President & Chief Executive Officer
“Securing a purchasing agreement with HCA Healthcare is an important commercial milestone for EBR. Establishing a purchasing pathway across one of the largest healthcare networks in the U.S. supports broader commercial access for the WiSE System and builds on the momentum of our U.S. rollout. It is also a signal that WiSE reimbursement supports adoption across larger networks.”
When big ASX news breaks, our subscribers know first
What this agreement means for WiSE System adoption
From two sites to a national network pathway
EBR is currently active at two HCA sites: St David’s Medical Center in Austin, Texas, and Medical City in Fort Worth, Texas. The purchasing agreement is designed to open the door well beyond these initial locations, providing a structured pathway for engagement across HCA’s broader hospital network.
Previously, procurement friction could slow access to individual sites. Under this agreement, EBR sales reps can now engage directly with physicians and administrators across HCA hospitals, removing barriers that would otherwise require facility-by-facility negotiation.
The reimbursement signal embedded in the CEO’s commentary carries additional weight. It suggests that WiSE reimbursement already supports adoption at scale, not just at single institutions, which has implications for how other large networks may assess the product.
What the agreement unlocks for EBR:
- Streamlined procurement and contracting pathways across HCA hospitals
- Direct physician and administrator engagement by EBR sales reps
- Potential expansion beyond the two currently active HCA sites
- A signal to other large networks that reimbursement supports WiSE adoption
HCA Healthcare at a glance
HCA Healthcare is one of the leading providers of healthcare services in the United States. Its network spans 190 hospitals and approximately 2,500 ambulatory sites of care across 19 states, based on figures as of 31 December 2025. HCA also has operations in the United Kingdom, though the announcement does not reference international operations as part of this agreement.
| Metric | Detail | U.S. States | As of |
|---|---|---|---|
| Hospitals | 190 | 19 | 31 Dec 2025 |
| Ambulatory sites of care | ~2,500 | 19 | 31 Dec 2025 |
Understanding the WiSE CRT System and why leadless pacing matters
Cardiac Resynchronisation Therapy (CRT) is a treatment used in heart failure patients where the heart’s left and right ventricles are not beating in coordination. CRT devices deliver precisely timed electrical pulses to resynchronise the heartbeat, which can improve cardiac function and quality of life for eligible patients.
Traditional CRT systems rely on coronary sinus leads, which are pacing wires positioned on the outside of the heart’s left ventricle. These leads have historically been a major source of complications, reliability issues, and sub-optimal pacing placement, limiting the therapy’s effectiveness for some patients.
The WiSE CRT System addresses this directly. It is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the left ventricle. The implant itself is roughly the size of a large grain of rice. Internal stimulation of the left ventricle is considered a potentially superior, more anatomically correct pacing location, and eliminating the need for a coronary sinus lead also potentially removes the complications associated with it.
WiSE is currently only available for sale in the U.S. For investors, purchasing agreements with hospital networks represent the commercial infrastructure that converts clinical adoption into scalable revenue opportunity.
The next major ASX story will hit our subscribers first
Building U.S. commercial momentum — what comes next
The HCA Healthcare agreement is best understood as part of a broader U.S. commercial rollout, rather than an isolated event. It adds structural scale to EBR’s go-to-market approach by establishing a repeatable procurement pathway within one of the country’s largest hospital networks.
The reimbursement signal cited by management also carries strategic read-through. If WiSE reimbursement already supports adoption at the large-network level, that positions EBR to pursue similar agreements with other major healthcare systems using the same commercial argument.
EBR sales reps now have direct access to engage across HCA’s network of hospitals, creating a more scalable model for physician engagement and device adoption than site-by-site outreach alone.
Key commercial indicators investors may wish to monitor:
- Expansion of active WiSE CRT System sites within HCA Healthcare beyond the current two
- Further purchasing agreements secured with other large U.S. hospital networks
- Ongoing WiSE CRT System adoption data and clinical use updates
- Any reimbursement or regulatory developments supporting broader U.S. access
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving healthcare announcement the moment it drops.